Investing
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
© Reuters. FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
(Reuters) – AbbVie (NYSE:) said on Thursday it will buy drugmaker ImmunoGen (NASDAQ:) for $10.1 billion, boosting its presence in the market for cancer treatments.
The drugmaker will pay $31.26 per ImmunoGen share in cash, representing a premium of 94.6% to the last closing price.
This transaction is expected to close in the middle of 2024, AbbVie said.
Read the full article here
-
Passive Income6 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles7 days ago
How to Develop Empowered Leaders Within Your Own Team
-
Side Hustles5 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles6 days ago
How Your Body Language Can Help Win a Disagreement
-
Investing6 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles6 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles7 days ago
Why the Best Time to Sell Your Business Is When You Least Expect It
-
Side Hustles4 days ago
Mark Zuckerberg Is Now Second Richest Person in the World